UBS analyst Trung Huynh says Novo Nordisk’s (NVO) CagriSema Segment 3 topline weight problems information “underwhelmed,” a favorable read-through to Eli Lilly (LLY) and Amgen (AMGN). CagriSema accomplished a mean weight lack of 20.4%, under Novo’s prior steerage of 25% and not so good as Lilly’s tirzepatide at a equivalent timepoint, the analyst tells traders in a analysis observe. UBS perspectives the CagriSema’s weight problems readout a favorable read-through to Lilly, “validating once more tirzepatide’s best-in-class profile.” It additionally perspectives Novo’s updates a favorable read-through to Amgen, announcing CagriSema’s efficacy now turns out most commonly in-line with MariTide, with most likely gastrointestinal intolerability problems, and may seem much less sexy with MariTide being a per 30 days titration routine. Printed first on TheFly – without equal supply for real-time, market-moving breaking monetary information. Check out Now>> See the highest shares beneficial through analysts >> Learn Extra on LLY: